{
    "clinical_study": {
        "@rank": "45440", 
        "brief_summary": {
            "textblock": "To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of\n      thalidomide in reducing weight loss in patients with HIV wasting syndrome."
        }, 
        "brief_title": "A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome", 
        "condition": [
            "HIV Infections", 
            "HIV Wasting Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Wasting Syndrome", 
                "Weight Loss", 
                "HIV Wasting Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive either thalidomide at 1 of 2 doses or placebo for 8\n      weeks. Patients who respond may continue in double-blinded treatment for an additional 4\n      weeks; nonresponding patients may receive thalidomide for up to 4 weeks. Per amendment,\n      patients may receive thalidomide for more than 12 weeks on a compassionate basis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Primary prophylaxis for opportunistic infections (if AFB blood culture negative).\n\n          -  Chronic suppressive therapy (maintenance) for opportunistic infections OTHER THAN\n             Mycobacterium avium Complex (MAC).\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Wasting syndrome.\n\n          -  Negative blood PCR for acid-fast bacteria (AFB) or a negative AFB blood culture\n             within 48 days prior to study entry.\n\n          -  No active opportunistic infection requiring systemic therapy within 6 weeks prior to\n             study entry.\n\n          -  Life expectancy of at least 6 weeks.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Chronic diarrhea (five or more unformed stools per day).\n\n          -  Peripheral neuropathy of grade 2 or worse.\n\n          -  Requirement for tube feeding or intravenous feeding.\n\n          -  Any disorder associated with moderate to severe edema (e.g., cirrhosis, nephrosis,\n             congestive heart failure).\n\n          -  Inability to ingest at least a maintenance diet based on present weight.\n\n          -  Any condition that precludes study participation.\n\n          -  Not under the care of a primary physician.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Chronic suppressive therapy (maintenance) or secondary prophylaxis for Mycobacterium\n             avium Complex (MAC) (suppressive therapy for other opportunistic infections is\n             allowed).\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiotherapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Any neoplasms other than non-medicated (i.e., not receiving systemic or intralesional\n             chemotherapy) Kaposi's sarcoma within 1 month prior to study entry.\n\n          -  Prior intolerance to thalidomide.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  ddC within 1 month prior to study entry.\n\n          -  Acute systemic therapy for opportunistic infections within 6 weeks prior to study\n             entry.\n\n          -  Agents that are anabolic, catabolic, or immunomodulatory (including interferons,\n             megestrol, dronabinol, oxandrolone, growth hormone, systemic corticosteroids, and\n             pentoxifylline) within 30 days prior to study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiotherapy within 6 weeks prior to study entry.\n\n        Required ONLY IF patient is on antiretroviral therapy:\n\n          -  Stable regimen of AZT or ddI for at least 1 month prior to study entry. Active drug\n             abuse within 3 months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "75", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002127", 
            "org_study_id": "230A", 
            "secondary_id": "W-001"
        }, 
        "intervention": {
            "intervention_name": "Thalidomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Thalidomide"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Cachexia", 
            "Thalidomide"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Marin County Specialty Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Redwood City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "940631633"
                    }, 
                    "name": "AIDS Community Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "921038681"
                    }, 
                    "name": "UCSD Med Ctr - Owen Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Kaiser Permanente Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherman Oaks", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91403"
                    }, 
                    "name": "Gottlieb Med Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "George Washington Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33146"
                    }, 
                    "name": "Community Research Initiative of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Kansas City AIDS Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07102"
                    }, 
                    "name": "Saint Michael's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Rockefeller Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Thomas Jefferson Med College"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981225314"
                    }, 
                    "name": "Advanced Research Management"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "9170807", 
            "citation": "Stirling D, Sherman M, Strauss S. Thalidomide. A surprising recovery. J Am Pharm Assoc (Wash). 1997 May-Jun;NS37(3):306-13. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002127"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1997"
    }, 
    "geocoordinates": {
        "AIDS Community Research Consortium": "37.485 -122.236", 
        "Advanced Research Management": "47.606 -122.332", 
        "Community Research Initiative of South Florida": "25.721 -80.268", 
        "George Washington Univ Med Ctr": "38.895 -77.036", 
        "Gottlieb Med Group": "34.149 -118.451", 
        "Kaiser Permanente Med Ctr": "37.775 -122.419", 
        "Kansas City AIDS Research Consortium": "39.1 -94.579", 
        "Marin County Specialty Clinic": "37.949 -122.524", 
        "Rockefeller Univ": "40.714 -74.006", 
        "Saint Michael's Med Ctr": "40.736 -74.172", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "Thomas Jefferson Med College": "39.952 -75.164", 
        "UCSD Med Ctr - Owen Clinic": "32.715 -117.157"
    }
}